Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Fingleton

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Cancer Genomics & Proteomics|September 20, 2007
Molecular targets in metastasis: lessons from genomic approachesBarbara Fingleton
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
CMT-3. CollaGenexBarbara Fingleton
Current Pharmaceutical Design|February 23, 2007
Matrix metalloproteinases as valid clinical targetsBarbara Fingleton
Gastroenterology|June 3, 2017
Making Cancer Quiescent: SPDEF De-Cycles Beta-CateninBarbara Fingleton
Biochimica Et Biophysica Acta. Molecular Cell Research|May 16, 2017
Matrix metalloproteinases as regulators of inflammatory processesBarbara Fingleton
Nature Medicine|February 6, 2010
Inflammatory proteinase slips into tumor cellsBarbara Fingleton
Expert Opinion on Therapeutic Targets|June 5, 2003
Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospectsBarbara Fingleton
Frontiers in Bioscience : a Journal and Virtual Library|September 9, 2005
Matrix metalloproteinases: roles in cancer and metastasisBarbara Fingleton
Seminars in Cell & Developmental Biology|August 19, 2007
MMPs as therapeutic targets--still a viable option?Barbara Fingleton
Clinical & Experimental Metastasis|May 11, 2019
Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasisDemond Williams, Barbara Fingleton
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Cancer Genomics & Proteomics|September 20, 2007
Molecular targets in metastasis: lessons from genomic approachesBarbara Fingleton
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
CMT-3. CollaGenexBarbara Fingleton
Current Pharmaceutical Design|February 23, 2007
Matrix metalloproteinases as valid clinical targetsBarbara Fingleton
Gastroenterology|June 3, 2017
Making Cancer Quiescent: SPDEF De-Cycles Beta-CateninBarbara Fingleton
Biochimica Et Biophysica Acta. Molecular Cell Research|May 16, 2017
Matrix metalloproteinases as regulators of inflammatory processesBarbara Fingleton
Nature Medicine|February 6, 2010
Inflammatory proteinase slips into tumor cellsBarbara Fingleton
Expert Opinion on Therapeutic Targets|June 5, 2003
Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospectsBarbara Fingleton
Frontiers in Bioscience : a Journal and Virtual Library|September 9, 2005
Matrix metalloproteinases: roles in cancer and metastasisBarbara Fingleton
Seminars in Cell & Developmental Biology|August 19, 2007
MMPs as therapeutic targets--still a viable option?Barbara Fingleton
Clinical & Experimental Metastasis|May 11, 2019
Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasisDemond Williams, Barbara Fingleton
Pageof 8